"2011 will be about growth stocks that are growing because they have unique products or services driven by customer demand," says small cap specialist Jim Oberweis, Jr.

The money manager and editor of The Oberweis Report explains, "Indeed, we think that investors will pay an increasing premium for growth when year-over-year increases become more difficult to find. Here our favorite issues that fit this bill.

"Our research indicates P/Es for small-cap growth stocks remain modestly below-average, but substantially higher than 2008 crisis levels and well within the "normal" range.

"Five years ago, we presented a strong case for investing in China; we felt so compelled by the opportunity that we expanded our research team and opened a regional research office in Hong Kong," says Jim Oberweis, Jr.

The money manager and editor of The Oberweis Report reviews his current outlook on China, as well as some of his favorite U.S.-listed small cap Chinese companies that are currently in our portfolio.

The advisor explains, "We just recently celebrated the five-year anniversary of our Oberweis China Opportunities Fund; since its inception, the fund returned an average annualized gain of 22.94%.

IMAX Corporation (NASDAQ: IMAX) is a recent featured stock from Jim Oberweis, Jr. Here, the money manager and editor of The Oberweis Report explains why his clients own 600,000 shares.

"IMAX specializes in motion picture technologies and large-format film presentations. IMAX designs and manufactures large-format digital and film-based theater systems.

"The company sells or leases such systems to its customers, and converts two-dimensional '2D' and three-dimensional '3D' Hollywood feature films for exhibition on such systems around the world.

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

Over 32 years, the portfolio in The Oberweis Report has returned an average gain of 21.2% a year vs. 7.9% for the S&P 500. Here, money manager and newsletter advisor Jim Oberweis, Jr. looks at Suntech Power Holdings Ltd. (NYSE: STP).

"Long-term results notwithstanding, 2008 has been humbling, to say the least. No other year in our history has been as challenging.

"But in our experience, the most favorable buying opportunities tend to fall after a period in which the market has not performed well.

"Although year-by-year results can be volatile, disciplined investors who remain fully invested in a portfolio of high-growth equities selected using our methodology have historically achieved an exceptional average rate of return over long periods of time.

"Suntech Power Holdings Co., Ltd is one of the leading solar energy companies in the world as measured by production output of photovoltaic, or PV, cells, with leading positions in key solar markets such as Germany and Spain.